Drugs & Targets FDA approves Emrelis for previously treated, advanced NSCLC with high c-Met protein overexpression May 16, 2025Vol.51 No.19
Drugs & Targets RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center May 16, 2025Vol.51 No.19
Drugs & Targets FDA approves Zynyz as first-line treatment for advanced anal cancer May 16, 2025Vol.51 No.19
Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit May 09, 2025Vol.51 No.18By Paul Goldberg and Jacquelyn Cobb
Guest Editorial George Weiner: Cancer centers are special, as are site visits in CCSG review May 09, 2025Vol.51 No.18By George J. Weiner
Cancer Policy $180M in NCI grants have been terminated by Trump administration, systematic review finds May 09, 2025Vol.51 No.18By Jacquelyn Cobb
Cancer Policy NIH to update policies and practices, halting subawards to foreign entities May 09, 2025Vol.51 No.18By Claire Marie Porter
Cancer Policy Women’s Health Initiative funding officially restored May 09, 2025Vol.51 No.18By Claire Marie Porter
Cancer Policy AACR calls on Congress to reject Trump’s FY2026 budget request for NIH May 09, 2025Vol.51 No.18By Jacquelyn Cobb
